Insomnia
Conditions
Brief summary
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in Chinses Healthy Subjects
Interventions
DRUGHEC83518 tablets
Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
DRUGPlacebo
placebo
Sponsors
Sunshine Lake Pharma Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
All are double-blind except the pre-trial group
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects who are willing and are able to provide a written informed consent to participate in the study. 2. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout the trial. 3. Subjects aged between 18 and 45 (both inclusive) years old. 4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥18 and ≤28 kg/m2 at screening. 5. Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG).
Exclusion criteria
1. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP antibodies at screening. 2. Subjects with history of digestive system,urinary system, liver,central nervous system, blood system, endocrine system,respiratory system,immune system,cardiovascular system,and/or malignant tumor or others medical conditions (such as history of mental illness, etc.) that are not suitable for clinical trial participation;Subjects with history of stroke, epilepsy, bipolar disorder/mania, high intraocular pressure, or acute angular-closure glaucoma. 3. Subjects with history of sleep-related illness. 4. Subjects with history of severe involuntary hypoglycemia 5. Known allergic reactions or hypersensitivity to any excipient of the drug formulation(s) ,or anaphylaxis physique. 6. Use of any prescription or non-prescription medications within 14 days prior to initial dosing,or Use of any medications known to inhibit or induce cytochrome P enzyme drug metabolism within 28 days prior to initial dosing. 7. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing. 8. Positive results from urine drug screen test. 9. History of alcoholism or drink regularly within 3 months prior to the study(defined as Alcohol consumption of \> 21 units/week), or positive results from alcohol breath test. 10. Regular smoking of more than 10 cigarettes per day within 3 months before administration of study drug. 11. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing. 12. Subjects who plan to receive or have had organ transplants. 13. Females who are lactating/breastfeeding, or positive result from pregnancy test for women of child-bearing potential. 14. Subjects who participated in another clinical trial within 3 months prior to initial dosing. 15. Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Adverse Events (AEs) | up to 5 days | Safety and Tolerability of HEC83518 by Assessment of the Number of Adverse Events (AEs) Following Administration in Single Ascending Dose . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters - AUC0-∞ | up to 96 hours | area under the concentration versus time curve (AUC) from time zero to infinity |
| PK parameters - Cmax | up to 96 hours | Geometric Mean of Maximum Observed Plasma Concentration of HEC83518 |
| PK parameters -tmax | up to 96 hours | time to peak |
| PK parameters -t½ | up to 96 hours | apparent terminal elimination half-life |
| PK parameters -Vz/F | up to 96 hours | apparent volume of distribution |
| PK parameters - MRT | up to 96 hours | the Mean Residence Time |
| PK parameters -CL/F | up to 96 hours | the Apparent Clearance |
Countries
China
Outcome results
None listed